Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23251749 | 0.96 | MTOR (0.58) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL24519414 | 0.94 | MTOR (0.59) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23251730 | 0.94 | MTOR (0.58) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL25064535 | 0.93 | MTOR (0.56) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23251499 | 0.92 | MTOR (0.64) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL24519520 | 0.87 | MTOR (0.66) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23251700 | 0.86 | MTOR (0.65) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL26067850 | 0.86 | MTOR (0.65) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL23157810 | 0.86 | MTOR (0.65) | MTORHDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL21527986 | 0.85 | MTOR (0.68) | MTORHDAC1HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885HDAC1 526/4885HDAC8 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.